Increased biglycan in aortic valve stenosis leads to the overexpression of phospholipid transfer protein via toll-like receptor 2

American Journal of Pathology

Volumn 176, Issue 6, 2010, Pages 2638-2645

  Derbali, Habib ^a   Bossé, Yohan ^b   Côté, Nancy ^a   Pibarot, Philippe ^b   Audet, Audrey ^a   Pépin, Andree ^a   Arsenault, Benoit ^b   Couture, Christian ^b   Després, Jean Pierre ^b   Mathieu, Patrick ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIGLYCAN; MATRIX PROTEIN; PHOSPHOLIPID TRANSFER PROTEIN; PROTEOGLYCAN; TOLL LIKE RECEPTOR 2; BGN PROTEIN, HUMAN; SCLEROPROTEIN;

AORTA VALVE STENOSIS; ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION PROFILING; GENETIC CODE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFLAMMATION; LEYDIG CELL; MICROARRAY ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; GENETICS; METABOLISM; PATHOLOGY;

AORTIC VALVE STENOSIS; BIGLYCAN; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION PROFILING; HUMANS; MICROARRAY ANALYSIS; PHOSPHOLIPID TRANSFER PROTEINS; PROTEOGLYCANS; TOLL-LIKE RECEPTOR 2;

EID: 77953215987     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.090541     Document Type: Article

References (24)

1. Rajamannan NM: Calcific aortic stenosis: lessons learned from experimental and clinical studies. Arterioscler Thromb Vasc Biol 2009, 29:162-168
2. Mohty D, Pibarot P, Despres JP, Cote C, Arsenault B, Cartier A, Cosnay P, Couture C, Mathieu P: Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis. Arterioscler Thromb Vasc Biol 2008, 28:187-193
3. Meng X, Ao L, Song Y, Babu A, Yang X, Wang M, Weyant MJ, Dinarello CA, Cleveland JC Jr, Fullerton DA: Expression of functional Toll-like receptors 2 and 4 in human aortic valve interstitial cells: potential roles in aortic valve inflammation and stenosis. Am J Physiol Cell Physiol 2008, 294:C29-C35
4. Yang X, Fullerton DA, Su X, Ao L, Cleveland JC Jr, Meng X: Proosteogenic phenotype of human aortic valve interstitial cells is associated with higher levels of Toll-like receptors 2 and 4 and enhanced expression of bone morphogenetic protein 2. J Am Coll Cardiol 2009, 53:491-500
5. Gustafsson M, Boren J: Mechanism of lipoprotein retention by the extracellular matrix. Curr Opin Lipidol 2004, 15:505-514
6. Tabas I, Williams KJ, Boren J: Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007, 116:1832-1844
7. O'Brien KD, Vuletic S, McDonald TO, Wolfbauer G, Lewis K, Tu AY, Marcovina S, Wight TN, Chait A, Albers JJ: Cell-associated and extracellular phospholipid transfer protein in human coronary atherosclerosis. Circulation 2003, 108:270-274
8. Schaefer L, Babelova A, Kiss E, Hausser HJ, Baliova M, Krzyzankova M, Marsche G, Young MF, Mihalik D, Gotte M, Malle E, Schaefer RM, Grone HJ: The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 2005, 115:2223-2233
9. Kunjathoor VV, Chiu DS, O'Brien KD, LeBoeuf RC: Accumulation of biglycan and perlecan, but not versican, in lesions of murine models of atherosclerosis. Arterioscler Thromb Vasc Biol 2002, 22:462-468
10. Desrumaux CM, Mak PA, Boisvert WA, Masson D, Stupack D, Jauhiainen M, Ehnholm C, Curtiss LK: Phospholipid transfer protein is present in human atherosclerotic lesions and is expressed by macrophages and foam cells. J Lipid Res 2003, 44:1453-1461
11. O'Brien KD, Lewis K, Fischer JW, Johnson P, Hwang JY, Knopp EA, Kinsella MG, Barrett PH, Chait A, Wight TN: Smooth muscle cell biglycan overexpression results in increased lipoprotein retention on extracellular matrix: implications for the retention of lipoproteins in atherosclerosis. Atherosclerosis 2004, 177:29-35
12. Williams KJ, Tabas I: The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995, 15:551-561
13. Tribble DL, Holl LG, Wood PD, Krauss RM: Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 1992, 93:189-199
14. Chang MY, Tsoi C, Wight TN, Chait A: Lysophosphatidylcholine regulates synthesis of biglycan and the proteoglycan form of macrophage colony stimulating factor. Arterioscler Thromb Vasc Biol 2003, 23:809-815
15. Settasatian N, Duong M, Curtiss LK, Ehnholm C, Jauhiainen M, Huuskonen J, Rye KA: The mechanism of the remodeling of high density lipoproteins by phospholipid transfer protein. J Biol Chem 2001, 276:26898-26905
16. Yang XP, Yan D, Qiao C, Liu RJ, Chen JG, Li J, Schneider M, Lagrost L, Xiao X, Jiang XC: Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression. Arterioscler Thromb Vasc Biol 2003, 23:1601-1607
17. Lie J, de CR, van GT, van HR, Scheek L, Sadeghi-Niaraki F, van TA: Elevation of plasma phospholipid transfer protein increases the risk of atherosclerosis despite lower apolipoprotein B-containing lipoproteins. J Lipid Res 2004, 45:805-811
18. Vikstedt R, Ye D, Metso J, Hildebrand RB, Van Berkel TJ, Ehnholm C, Jauhiainen M, Van EM: Macrophage phospholipid transfer protein contributes significantly to total plasma phospholipid transfer activity and its deficiency leads to diminished atherosclerotic lesion development. Arterioscler Thromb Vasc Biol 2007, 27:578-586
19. Babu AN, Meng X, Zou N, Yang X, Wang M, Song Y, Cleveland JC, Weyant M, Banerjee A, Fullerton DA: Lipopolysaccharide stimulation of human aortic valve interstitial cells activates inflammation and osteogenesis. Ann Thorac Surg 2008, 86:71-76
20. Xu XH, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC, Luthringer D, Xu XP, Rajavashisth TB, Yano J, Kaul S, Arditi M: Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001, 104:3103-3108 (Pubitemid 34014065)
21. Miller YI, Viriyakosol S, Worrall DS, Boullier A, Butler S, Witztum JL: Toll-like receptor 4-dependent and -independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages. Arterioscler Thromb Vasc Biol 2005, 25:1213-1219
22. Otto CM: Calcific aortic stenosis-time to look more closely at the valve. N Engl J Med 2008, 359:1395-1398
23. Khalil MF, Wagner WD, Goldberg IJ: Molecular interactions leading to lipoprotein retention and the initiation of atherosclerosis. Arterioscler Thromb Vasc Biol 2004, 24:2211-2218
24. Erickson B, Sperber K, Frishman WH: Toll-like receptors: new therapeutic targets for the treatment of atherosclerosis, acute coronary syndromes, and myocardial failure. Cardiol Rev 2008, 16:273-279